US 11,939,297 B2
Cannabinoid receptor mediating compounds
George Kunos, Bethesda, MD (US); Malliga Iyer, Germantown, MD (US); Resat Cinar, Bethesda, MD (US); and Kenner C. Rice, Bethesda, MD (US)
Assigned to The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The USA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Feb. 10, 2023, as Appl. No. 18/108,264.
Application 16/870,093 is a division of application No. 15/674,365, filed on Aug. 10, 2017, granted, now 10,683,270, issued on Jun. 16, 2020.
Application 18/108,264 is a continuation of application No. 17/956,313, filed on Sep. 29, 2022, abandoned.
Application 17/956,313 is a continuation of application No. 16/870,093, filed on May 8, 2020, granted, now 11,485,709, issued on Nov. 1, 2022.
Application 15/674,365 is a continuation of application No. 14/442,383, granted, now 9,765,031, issued on Sep. 19, 2017, previously published as PCT/US2013/069686, filed on Nov. 12, 2013.
Claims priority of provisional application 61/725,949, filed on Nov. 13, 2012.
Prior Publication US 2023/0219896 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/06 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01)
CPC C07D 231/06 (2013.01) [C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01)] 2 Claims
 
1. A compound of the following formula:

OG Complex Work Unit Chemistry
wherein
R′ is CF3; and
A is

OG Complex Work Unit Chemistry